Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
暂无分享,去创建一个
Kun Wang | D. Wei | Yi-Ping Lin | M. Cheng | Liulu Zhang | Yi Zhang | Xiaosheng Zhuang | Yuanqi Chen | Jiachen Zou
[1] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[2] N. Masuda,et al. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial , 2021, Breast Cancer Research and Treatment.
[3] P. Fasching,et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] C. Perou,et al. TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] E. Winer,et al. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] V. Welch,et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. , 2019, The Cochrane database of systematic reviews.
[7] P. Fasching,et al. GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (H , 2019, Journal of Clinical Oncology.
[8] F. Caramelo,et al. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis , 2019, Hereditary Cancer in Clinical Practice.
[9] M. Rezai,et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Ceppi,et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Shou‐Tung Chen,et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. , 2018 .
[12] Paul Ellis,et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.
[13] W. Symmans,et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[14] P. Fasching,et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.
[15] Fang Yang,et al. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy , 2017, Cancer biology & therapy.
[16] M. Frey,et al. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature , 2017, Gynecologic Oncology Research and Practice.
[17] Anne M Wallace,et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. , 2016, The New England journal of medicine.
[18] Z. Szallasi,et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.
[19] A. Richardson,et al. Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis , 2016 .
[20] N. Hansen,et al. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579) , 2015, Breast Cancer Research and Treatment.
[21] M. Rezai,et al. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. , 2015 .
[22] James M Ford,et al. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Berry,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[25] M. Rezai,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[26] A. Godwin,et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing , 2014, Breast Cancer Research and Treatment.
[27] S. Henikoff,et al. Doxorubicin, DNA torsion, and chromatin dynamics. , 2014, Biochimica et biophysica acta.
[28] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[29] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[30] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[31] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[32] Z. Szallasi,et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.
[33] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[34] E. Alli,et al. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells , 2011, BMC pharmacology.
[35] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[36] Hannah R Rothstein,et al. A basic introduction to fixed‐effect and random‐effects models for meta‐analysis , 2010, Research synthesis methods.
[37] P. Johnston,et al. The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.
[38] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[39] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[40] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[41] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.